“All the risks are to the innocent children and all of the billion-dollar rewards go to the government-protected pharmaceuticals,” said Rep. Louie Gohmert (R-Texas), after advisors to the U.S. Food and Drug Administration today voted 21-0 to recommend Pfizer’s and Moderna’s COVID-19 vaccines for infants and young children.
The U.S. Food and Drug Administration’s (FDA) vaccine advisory panel today unanimously voted 21-0 to recommend Pfizer and Moderna’s COVID-19 vaccines for infants and young children, stating the totality of the evidence available shows the benefits of the vaccines outweigh the risks of use.
Pfizer’s three-dose vaccine would cover children 6 months to 5 years old, while Moderna’s two-dose vaccine covers children 6 months to 6 years old.
Depending on whether the FDA and Centers for Disease Control and Prevention (CDC) accept the recommendations of their advisory panels, White House officials have said the administration of vaccines for these age groups could start as early as June 21.
The Vaccines and Related Biological Products Advisory Committee (VRBPAC) ignored pleas from experts, the vaccine injured and a congressman representing 17 other lawmakers to halt authorization until questions about the safety and efficacy of COVID-19 vaccines for the nation’s youngest children could be properly addressed.